M J Moore

Development and Validation of a Limited Sampling Strategy for 5‐Fluorouracil Given by Bolus Intravenous Administration

M. Moore, J. Thiessen, P Bunting, 1993, Therapeutic drug monitoring.

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

P. Albers, M. Moore, I. Bodrogi, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer

R. Goldberg, D. Tu, M. Moore, 2005, British Journal of Cancer.

Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.

A R Willan, I. Tannock, T. Smith, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

R. Simes, D. Tu, M. Moore, 2013, British Journal of Cancer.

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

D. V. Von Hoff, M. Moore, H. Burris, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

D. Osoba, I. Tannock, M. Stockler, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.